Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Korosho to Revise Priority NDA Review System
September 8, 2003
- BUSINESS NEWS IN BRIEF
September 1, 2003
- DIAGNOSTIC NEWS IN BRIEF
September 1, 2003
- WEBSITE NEWS
September 1, 2003
- MEDICAL DEVICE NEWS IN BRIEF
September 1, 2003
- Financial Results in 1st Quarter
September 1, 2003
- WORLD NEWS IN BRIEF
September 1, 2003
- Semianual Financial Results
September 1, 2003
- Yamanouchi Licenses Bone Morphogenetic Protein to Medtronic Sofamor Danek
September 1, 2003
- NEW PRODUCTS
September 1, 2003
- 4 New Drugs, Including Pegasys, Visudyne Recommended for Approval
September 1, 2003
- Insurance Medical Costs Fell 0.7% in FY2002: Korosho
September 1, 2003
- 1 in 5 Japanese May Suffer from Diabetes: Korosho Survey
September 1, 2003
- BI to Further Collaborate with Japanese Firms: Prof. Krebs
September 1, 2003
- REGULATORY NEWS IN BRIEF
September 1, 2003
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
September 1, 2003
- ON THE MOVE
September 1, 2003
- Dainippon to Promote Better Cancer Pain Management
September 1, 2003
- Don Quijote to Provide Free OTC Drugs in Late Night Emergencies
September 1, 2003
- Merck & Co. Determined to Acquire All Shares of Banyu
September 1, 2003
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…